"ALS reversals": demographics, disease characteristics, treatments, and co-morbidities.

Published

Journal Article

OBJECTIVE: To identify differences in demographics, disease characteristics, treatments, and co-morbidities between patients with "amyotrophic lateral sclerosis (ALS) reversals" and those with typically progressive ALS. METHODS: Cases of possible ALS reversals were found in prior publications, in the Duke ALS clinic, through self-referral or referral from other Neurologists, and on the internet. Of 89 possible reversals identified, 36 cases were included because chart or literature review confirmed their diagnosis and a robust, sustained improvement in at least one objective measure. Controls were participants in the Pooled Resource Open-Access ALS Clinical Trials database and the National ALS Registry. Cases and controls were compared using descriptive statistics. RESULTS: ALS reversals were more likely to be male, have limb onset disease, and initially progress faster. The prevalences of myasthenia gravis (MG) and purely lower motor neuron disease in cases were higher than estimates of these prevalences in the general population. The odds of taking curcumin, luteolin, cannabidiol, azathioprine, copper, glutathione, vitamin D, and fish oil were greater for cases than controls. CONCLUSIONS: When compared to patients with typically progressive ALS, patients with reversals differed in their demographics, disease characteristics, and treatments. While some of these patients may have had a rare antibody-mediated ALS mimicker, such as atypical myasthenia gravis, details of their exams, EMGs and family histories argue that this was unlikely. Instead, our data suggest that ALS reversals warrant evaluation for mechanisms of disease resistance and that treatments associated with multiple ALS reversals deserve further study.

Full Text

Duke Authors

Cited Authors

  • Harrison, D; Mehta, P; van Es, MA; Stommel, E; Drory, VE; Nefussy, B; van den Berg, LH; Crayle, J; Bedlack, R; Pooled Resource Open-Access ALS Clinical Trials Consortium,

Published Date

  • November 2018

Published In

Volume / Issue

  • 19 / 7-8

Start / End Page

  • 495 - 499

PubMed ID

  • 29607695

Pubmed Central ID

  • 29607695

Electronic International Standard Serial Number (EISSN)

  • 2167-9223

Digital Object Identifier (DOI)

  • 10.1080/21678421.2018.1457059

Language

  • eng

Conference Location

  • England